PATENTS

Recent patents in neoantigens and neoepitopes Patent number Description Assignee Inventor Date AU2016264623 A1 A pharmaceutical composition comprising a plurality of neoantigenic The Broad Institute Fritsch EF, 12/7/2017 and a pharmaceutically acceptable carrier, each neoanti- (Cambridge, MA, USA), Hacohen N, genic comprising a tumor-specific neoepitope capable of Dana-Farber Rooney MS, binding to an HLA in a subject, each tumor-specific neoepit- Institute (Boston), Shukla SA, Wu CJ, ope comprising a tumor-specific present in a tumor, wherein The General Hospital Bachireddy P, Sun J (i) the composition comprises neoantigenic peptides comprising Corporation (Boston) tumor-specific present in at least 1% of subjects in a population of subjects suffering from cancer; (ii) the composition comprises neoantigenic peptides comprising tumor-specific neoepi- topes which bind to HLA present in at least 5% of subjects in the population; and (iii) the composition comprises at least one neoantigenic peptide capable of eliciting an immune response against a tumor present in at least 5% of the subjects in the population of subjects suffering from cancer. US 9,835,631 A sandwich immunoassay for detecting cross-linked PIIINP that Nordic Bioscience (Herlev, Genovese F, 12/5/2017 has at least two strands of PIIINP joined together by interstrand Denmark) Nielsen MJ, Larsen L, cross-linking each having a C-terminal neoepitope of PIIINP that is Oersnes-Leeming DJ, generated by N-protease cleavage of intact type III procollagen. Also, Karsdal M a method for evaluating the efficacy of an antagonist drug targeting lysyl oxidases via the immunoassay and a kit containing a solid sup- port binding the first monoclonal antibody and containing the second monoclonal antibody. WO2017205810 A1 Methods for constructing and producing recombinant adenovirus- Etubics (Seattle), Nant Jones FR, Rice A, 11/30/2017 based vector containing nucleic acid sequences encoding Holdings (Los Angeles), Soon-Shiong P, tumor neoantigens and neoepitopes that allow for in Nantcell (Culver City, CA, Niazi K, Rabizadeh S individuals with preexisting immunity to adenovirus. Also, methods USA) and compositions for the treatment of cancer using immunotherapy based on recombinant adenovirus-based vectors combined with engi- neered natural killer cells. The methods and compositions further comprise a nucleic acid encoding an immunological fusion partner. WO2016172722 A1 Compositions and methods directed to cancer neoepitopes and uses NantOmics (Rockville, MD, Nguyen A, Niazi K, 4/25/2016 of such neoepitopes, especially to generate synthetic antibodies USA), Nant Holdings (Los Soon-Shiong P, against neoepitopes that may then be employed in the manufacture Angeles) Rabizadeh S, of a therapeutic agent comprising a synthetic antibody against a neo- Benz SC , and most preferably in combination with a cellular or non- cellular component for use as a diagnostic or therapeutic agent. US 9,238,064 Cell-based immunotherapy (e.g., immunization or ) may University of Miami Podack ER, 1/19/2016 be improved by frequent administration to a human subject of alloge- (Miami) Rosenblatt JD, neic cancer cells secreting a modified heat shock protein (e.g., gp96), Yamazaki K depletion of B cells in the subject, or both. (e.g., epitope derived from neoantigen or tumor antigen of allogeneic or syngeneic cancer cells) may induce a specific immune response in the subject. US 9,096,674 Antibodies which bind specifically to an immune complex of pro- Siemens Healthcare Ehm MM, Fischer B, 8/4/2015 thrombin fragment F2/F1+2 and an F2/F1+2 neoepitope-specific Diagnostics Products Althaus H, Barten R, antibody fragment, and to the preparation and the use thereof in (Marburg, Germany) Teigelkamp S methods for determining F2/F1+2. US 8,580,529 A method for detecting or monitoring the presence of protein frag- AnaMar (Gothenburg, Danfelter M, 11/12/2013 ments, cleaved at novel cleaving sites near the N-terminal part of Sweden) Onnerfjord P, the collagen IX alpha 1 chain, close to the C-terminal part of the Heinegard D NC4 domain, and at the COL3 domain close to the NC3 domain. Neoepitope antibodies against the neoepitopes were created by the cleavages and an epitope in the cleaved N-terminal part of the NC4 domain unique to collagen IX. Also, a diagnostic kit and antibodies useful in carrying out such methods. US 8,394,385 Compositions and methods for the induction of a strong CD8 T-cell Bavarian Nordic Hausmann J, Baur K, 3/12/2013 response to a specific antigen(s). The combination of an early/late (Kvistgaard, Denmark) Brinkmann K © 2018 Nature America, Inc., part of Springer Nature. All rights reserved. All rights part Nature. of Springer Inc., America, Nature © 2018 hybrid promoter directing strongly enhanced early expression of a neo- antigen with at least three immunization rounds resulted in a highly efficient neoantigen-specific CD8 T-cell response. This combination reversed the immunodominance hierarchy and converted a moderately immunogenic and subdominant CD8 T-cell epitope into the immuno- dominant epitope. Source: European Patent Office (https://www.epo.org), United States Patent and Trademark Office (http://www.uspto.gov).

146 VOLUME 36 NUMBER 2 FEBRUARY 2018 NATURE BIOTECHNOLOGY